Stress Levels Periodontitis and Metabolic Syndrome

November 11, 2026 updated by: Dilek KARADOĞAN, Recep Tayyip Erdogan University Training and Research Hospital

Evaluation of Salivary Cortisol, Dehydroepiandrosterone, Chromogranin A, and Psychological Stress Levels in Patients With Periodontitis and Metabolic Syndrome

The purpose of this observational study is to evaluate the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A, as well as the levels of psychological stress, in patients with periodontitis and/or metabolic syndrome. The primary research question the study aims to address is:

- Are the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A and psychological stress in patients with periodontitis and/or metabolic syndrome associated with their periodontal status and metabolic syndrome?

Participants-categorized into a control group, those with periodontitis only, those with metabolic syndrome only, and those with both periodontitis and metabolic syndrome-will undergo a clinical periodontal examination, provide saliva samples for the assessment of cortisol, dehydroepiandrosterone, and chromogranin A levels, and complete validated scales designed to measure psychological stress. The findings will help clarify the relationship between psychological stress, stress-related salivary biomarkers, metabolic syndrome, and periodontal health.

Study Overview

Detailed Description

Within the scope of the study, the Rosenberg Self-Esteem Scale and the Social Appearance Anxiety Scale will be administered. Salivary markers-cortisol, dehydroepiandrosterone, and chromogranin A-will be analyzed using the ELISA method. Periodontal clinical parameters (plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment loss) will be measured.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Rize Province
      • Rize, Rize Province, Turkey (Türkiye), 53020
        • Department of Periodontology of the Faculty of Dentistry of Recep Tayyip Erdogan University
        • Contact:
          • RTEU Faculty of Dentistry, Department of Periodontology
          • Phone Number: +90 464 222 00 00
          • Email: dis@erdogan.edu.tr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Individuals who presented to the Internal Medicine Outpatient Clinic at the Recep Tayyip Erdoğan University Faculty of Medicine Training and Research Hospital and met the diagnostic criteria for metabolic syndrome as defined by the American Diabetes Association (ADA) or the International Diabetes Federation (IDF); healthy volunteers who presented to the Periodontology Clinic at the Recep Tayyip Erdoğan University Faculty of Dentistry; and individuals who were diagnosed with periodontitis but did not meet the criteria for metabolic syndrome.

Description

Inclusion Criteria:

  • Individuals between the ages of 18 and 65,
  • Those who have at least 20 natural teeth,
  • Individuals who have provided written informed consent for participation in the research
  • Individuals diagnosed with periodontitis and/or metabolic syndrome

Exclusion Criteria:

  • Individuals who have received periodontal treatment (surgical or non-surgical) within the last 6 months,
  • Individuals with a history of using antibiotics, anti-inflammatory drugs, or immunosuppressive medications within the last 3 months,
  • Individuals with a history of systemic disease who do not meet the criteria for metabolic syndrome (e.g., malignancy, autoimmune diseases, liver/kidney failure),
  • Individuals who have been diagnosed with a psychiatric disorder or are undergoing regular psychiatric treatment,
  • Pregnant or breastfeeding women,
  • Individuals with physical or mental disabilities that prevent them from maintaining their oral hygiene.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Healthy Control Group

Individuals with no clinical or radiographic signs of periodontal disease and no history of systemic disease

Periodontitis Group (Systemically Healthy)

Individuals diagnosed with periodontitis according to the 2018 American Academy of Periodontology classification, but with no history of systemic disease

Metabolic Syndrome Group (Periodontally Healthy)

Individuals diagnosed with metabolic syndrome according to American Diabetes Association or International Diabetes Federation criteria, but without periodontitis

Periodontitis + Metabolic Syndrome Group

Individuals diagnosed with both metabolic syndrome and periodontitis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plaque Index
Time Frame: Day 1

Plaque Index (PI) (Silness and Löe, 1964) This index is used to evaluate the amount of dental plaque accumulation on tooth surfaces. Each tooth's four surfaces (buccal, lingual, mesial, distal) are examined using a probe or visually. Each surface is scored from 0 to 3. The average score is calculated for each tooth. The overall plaque index is obtained by averaging the scores from all examined teeth.

Score Description

0 No plaque.

  1. No visible plaque, but a slight film of plaque is detected when a probe is run along the gingival margin.
  2. Visible plaque along the gingival margin, forming a continuous band.
  3. Abundant plaque covering the gingival area and extending toward the middle of the tooth surface, including the interproximal spaces.
Day 1
Gingival Index
Time Frame: Day 1

The Gingival Index is used to assess the presence and severity of gingival inflammation (gingivitis). Four surfaces of each tooth (buccal, lingual, mesial, distal) are examined visually and with a periodontal probe. The evaluation considers color changes, edema (swelling), tissue consistency, and bleeding on probing. Each surface is scored from 0 to 3. The average score per tooth is calculated, and then the overall average is used to determine the individual's GI score.

Score Description

0 Healthy gingiva: normal color and texture, no bleeding

  1. Mild inflammation: slight color change and swelling, no bleeding on probing
  2. Moderate inflammation: redness, edema, soft tissue, bleeding on probing
  3. Severe inflammation: marked redness and swelling, ulceration, possible spontaneous bleeding
Day 1
Bleeding on Probing Index
Time Frame: Day 1

This index is used to assess the presence and severity of gingival inflammation by observing bleeding after gentle pressure is applied to the gingival sulcus using a periodontal probe. A thin periodontal probe is gently inserted into the gingival sulcus with light pressure (approximately 20-25 grams). Bleeding occurring within 10-30 seconds is observed. Each measurement site is recorded as either "bleeding present" or "bleeding absent." Presence of bleeding is an early and sensitive indicator of gingival inflammation.

Score Description: 0 No bleeding 1 Bleeding present (mild or severe)

Day 1
Probing Pocket Depth
Time Frame: Day 1

Using a Williams periodontal probe, the distance between the gingival margin and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual.

Measurement Interpretation

1-3 mm Healthy sulcus

4-5 mm Shallow to moderate pocket

≥6 mm Deep periodontal pocket (advanced disease)

Day 1
Clinical Attachment Loss
Time Frame: Day 1

Using a Williams periodontal probe, the distance between the enamel-cementum junction and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual.

Clinical Attachment Loss Value Interpretation

0-1 mm Healthy / minimal loss

2-3 mm Mild attachment loss

4-5 mm Moderate attachment loss

≥6 mm Severe attachment loss

Day 1
Collection of Saliva Samples
Time Frame: Day 2

Prior to saliva collection, participants will be instructed to abstain from caffeine and/or nicotine for at least 4 hours and alcohol for at least 24 hours. Saliva will be collected between 9:00 AM and 11:00 AM to minimize circadian variations. Unstimulated saliva flow rate will be collected over 10 minutes using the spitting method and will be expressed in mL/min.

Day 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rosenberg Self-Esteem Scale Score
Time Frame: Day 1

A four-point scale will be used to score responses to the 10 items. Positive questions are scored as 3: Strongly agree; 2: Agree; 1: Disagree; and 0: Strongly disagree, while negative questions are scored as 0: Strongly agree; 1: Agree; 2: Disagree; and 3: Strongly disagree. According to the final total score of the Rosenberg Self-Esteem Scale scores between 0-15, 15-25, and 25-30 indicate low, normal, and high self-esteem levels, respectively.

Day 1
Social Appearance Anxiety Scale Score
Time Frame: Day 1

Social Appearance Anxiety Scale 16-item scale concerns how patients feel about their appearance. A score of 1 to 5 is given for each item as follows: 1, completely disagree; 2, partially disagree; 3, unsure; 4, partially agree; 5, I completely agree. Scores range from 16 to 80, with higher scores representing greater social appearance anxiety.

Day 1
Concentration of Cortisol, Dehydroepiandrosterone and Chromogranin A
Time Frame: approximately in the 4th month

Salivary cortisol, Dehydroepiandrosterone and Chromogranin A will be obtained from unstimulated whole saliva samples. Saliva samples will be stored at -20°C until analyzed. Human salivary cortisol, Dehydroepiandrosterone, and Chromogranin A will be measured using radioenzyme immunoassay using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.

approximately in the 4th month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

March 15, 2027

Study Completion (Estimated)

April 19, 2027

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe